Biogen and Eisai have received approval from the FDA for an at-home shot version of their Alzheimer's treatment, Leqembi. This highly anticipated treatment is set to provide patients with a more accessible option for managing the disease. The approval marks a significant milestone in the fight against Alzheimer's.